DOCSLIB.ORG

Investigating the Role of the ETS Transcription Factor ELK1 in Stem Cell Transcription

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Investigating the Role of the ETS Transcription Factor ELK1 in Stem Cell Transcription Investigating the role of the ETS transcription factor ELK1 in stem cell transcription A thesis submitted to the University of Manchester for the degree of Doctor of Philosophy in the Faculty of Biology, Medicine and Health 2017 Ian E. Prise Division of Molecular & Cellular Function School of Biological Sciences I. Table of Contents II. List of Figures ...................................................................................................................................... 5 III. Abstract .............................................................................................................................................. 7 IV. Declaration ......................................................................................................................................... 8 V. Copyright Statement ........................................................................................................................... 8 VI. Experimental Contributions ............................................................................................................... 9 VII. Acknowledgments .......................................................................................................................... 10 1. Introduction ...................................................................................................................................... 12 1.I Pluripotency ................................................................................................................................. 12 1.II Chromatin ................................................................................................................................... 13 1.II.A Histones ............................................................................................................................... 14 1.III Transcription .............................................................................................................................. 15 1.III.A Transcriptional activation ................................................................................................... 15 1.III.B Transcriptional repression .................................................................................................. 17 1.III.C Polycomb repression complexes ........................................................................................ 20 1.IV The mitogen activated protein kinase pathways....................................................................... 24 1.IV.A Response to different stimuli ............................................................................................. 24 1.V The ETS transcription factor family............................................................................................. 25 1.VI ELK1............................................................................................................................................ 26 1.VI.A Structure of ELK1 ................................................................................................................ 26 1.VI.B Relationship to other ETS proteins ..................................................................................... 29 1.VI.C Biological processes involving ELK1 .................................................................................... 30 2. Project aims....................................................................................................................................... 32 3. Materials and Methods ..................................................................................................................... 35 3.I Lab techniques ............................................................................................................................. 35 3.I.A Cell Culture ........................................................................................................................... 35 3.I.B Retinoic acid treatment ........................................................................................................ 35 3.I.C Mesoderm Differentiation .................................................................................................... 36 3.I.D Neural Progenitor Cell Differentiation.................................................................................. 36 3.I.E IL-6 Cell stimulation ............................................................................................................... 36 3.I.F shRNA treatment ................................................................................................................... 36 3.I.G siRNA transfection ................................................................................................................ 36 3.I.H Crosslinking and lysing cells .................................................................................................. 37 3.I.I Chromatin Immunoprecipitation ........................................................................................... 37 3.I.J Co-Immunoprecipitation ....................................................................................................... 38 3.I.K RNA purification .................................................................................................................... 38 3.I.L PCR (siELK1, MIM and NPC treatments) ................................................................................ 38 3.I.M RT-PCR (shELK1 and RA treatments) ................................................................................... 39 3.I.N Rapid immunoprecipitation of endogenous proteins .......................................................... 39 3.I.O Western Blot Analysis ........................................................................................................... 40 3.II Bioinformatic analysis ................................................................................................................. 40 3.II.A ChIP-seq analysis.................................................................................................................. 40 3.II.B RNA-seq analysis .................................................................................................................. 41 3.II.C Peak Intersections ................................................................................................................ 41 3.II.D Tag Density Graphs .............................................................................................................. 41 2 3.II.E Motif Analysis ....................................................................................................................... 41 3.II.F Graphics ................................................................................................................................ 42 3.II.G Accession numbers .............................................................................................................. 42 3.II.H Primer Design ...................................................................................................................... 42 3.II.I Statistical Analysis ................................................................................................................. 42 3.III Materials .................................................................................................................................... 42 3.III.A siRNAs ................................................................................................................................. 42 3.III.B PCR Primers ......................................................................................................................... 42 3.III.C ChIP Solutions ..................................................................................................................... 46 3.III.D Western Blot Solutions ....................................................................................................... 48 3.III.E Antibodies ........................................................................................................................... 48 4. Results ............................................................................................................................................... 50 4.I ELK1 binding regions can be divided into different modules ...................................................... 50 4.I.A Genomic distribution of ELK1 modules ................................................................................ 50 4.I.B ELK1 loci with low ERK2 enrichment correlate with high PRC2 enrichment ........................ 52 4.I.C ELK1 loci with high SUZ12 enrichment correlate with low enrichment of active histone modifications ................................................................................................................... 54 4.I.D ELK1 loci with high SUZ12 enrichment correlate with genes enriched for developmental GO terms .............................................................................................................. 56 4.I.E An ELK1+SUZ12 binding module is H1-hESC specific ............................................................ 58 4.I.F ELK1 loci with low GABPA enrichment correlate with high PRC2 enrichment ..................... 60 4.I.G Conclusion Part1 ................................................................................................................... 65 4.II ELK1 does not interact with PRC2 ............................................................................................... 67 4.II.A An
Load more

Recommended publications
  • 1 Evidence for Gliadin Antibodies As Causative Agents in Schizophrenia
    1 Evidence for gliadin antibodies as causative agents in schizophrenia. C.J.Carter PolygenicPathways, 20 Upper Maze Hill, Saint-Leonard’s on Sea, East Sussex, TN37 0LG [email protected] Tel: 0044 (0)1424 422201 I have no fax Abstract Antibodies to gliadin, a component of gluten, have frequently been reported in schizophrenia patients, and in some cases remission has been noted following the instigation of a gluten free diet. Gliadin is a highly immunogenic protein, and B cell epitopes along its entire immunogenic length are homologous to the products of numerous proteins relevant to schizophrenia (p = 0.012 to 3e-25). These include members of the DISC1 interactome, of glutamate, dopamine and neuregulin signalling networks, and of pathways involved in plasticity, dendritic growth or myelination. Antibodies to gliadin are likely to cross react with these key proteins, as has already been observed with synapsin 1 and calreticulin. Gliadin may thus be a causative agent in schizophrenia, under certain genetic and immunological conditions, producing its effects via antibody mediated knockdown of multiple proteins relevant to the disease process. Because of such homology, an autoimmune response may be sustained by the human antigens that resemble gliadin itself, a scenario supported by many reports of immune activation both in the brain and in lymphocytes in schizophrenia. Gluten free diets and removal of such antibodies may be of therapeutic benefit in certain cases of schizophrenia. 2 Introduction A number of studies from China, Norway, and the USA have reported the presence of gliadin antibodies in schizophrenia 1-5. Gliadin is a component of gluten, intolerance to which is implicated in coeliac disease 6.
    [Show full text]
  • Manual: Pathdetect Reporter Cell Lines
    PathDetect Reporter Cell Lines INSTRUCTION MANUAL Catalog #800050 (PathDetect HLR Cell Line) #800055 (HLR-Elk1 Cell Line) #800060 (HLR-CHOP Cell Line) #800065 (HLR-CREB Cell Line) Revision A BN #800050-12 For In Vitro Use Only 800050-12 LIMITED PRODUCT WARRANTY This warranty limits our liability to replacement of this product. No other warranties of any kind, express or implied, including without limitation, implied warranties of merchantability or fitness for a particular purpose, are provided by Agilent. Agilent shall have no liability for any direct, indirect, consequential, or incidental damages arising out of the use, the results of use, or the inability to use this product. ORDERING INFORMATION AND TECHNICAL SERVICES United States and Canada Agilent Technologies Stratagene Products Division 11011 North Torrey Pines Road La Jolla, CA 92037 Telephone (858) 373-6300 Order Toll Free (800) 424-5444 Technical Services (800) 894-1304 Internet [email protected] World Wide Web www.stratagene.com Europe Location Telephone Fax Technical Services Austria 0800 292 499 0800 292 496 0800 292 498 Belgium 00800 7000 7000 00800 7001 7001 00800 7400 7400 0800 15775 0800 15740 0800 15720 France 00800 7000 7000 00800 7001 7001 00800 7400 7400 0800 919 288 0800 919 287 0800 919 289 Germany 00800 7000 7000 00800 7001 7001 00800 7400 7400 0800 182 8232 0800 182 8231 0800 182 8234 Netherlands 00800 7000 7000 00800 7001 7001 00800 7400 7400 0800 023 0446 +31 (0)20 312 5700 0800 023 0448 Switzerland 00800 7000 7000 00800 7001 7001 00800 7400 7400 0800 563 080 0800 563 082 0800 563 081 United Kingdom 00800 7000 7000 00800 7001 7001 00800 7400 7400 0800 917 3282 0800 917 3283 0800 917 3281 All Other Countries Please contact your local distributor.
    [Show full text]
  • Expression of Oncogenes ELK1 and ELK3 in Cancer
    Review Article Annals of Colorectal Cancer Research Published: 11 Nov, 2019 Expression of Oncogenes ELK1 and ELK3 in Cancer Akhlaq Ahmad and Asif Hayat* College of Chemistry, Fuzhou University, China Abstract Cancer is the uncontrolled growth of abnormal cells anywhere in a body, ELK1 and ELK3 is a member of the Ets-domain transcription factor family and the TCF (Ternary Complex Factor) subfamily. Proteins in this subfamily regulate transcription when recruited by SRF (Serum Response Factor) to bind to serum response elements. ELK1 and ELK3 transcription factors are known as oncogenes. Both transcription factors are proliferated in a different of type of cancer. Herein, we summarized the expression of transcription factor ELK1 and ELK3 in cancer cells. Keywords: ETS; ELK1; ELK3; Transcription factor; Cancer Introduction The ETS, a transcription factor of E twenty-six family based on a dominant ETS amino acids that integrated with a ~10-basepair element arrange in highly mid core sequence 5′-GGA(A/T)-3′ [1-2]. The secular family alter enormous 28/29 members which has been assigned in human and mouse and similarly the family description are further sub-divided into nine sub-families according to their homology and domain factor [3]. More importantly, one of the subfamily members such as ELK (ETS-like) adequate an N-terminal ETS DNA-binding domain along with a B-box domain that transmit the response of serum factor upon the formation of ternary complex and therefore manifested as ternary complex factors [4]. Further the ELK sub-divided into Elk1, Elk3 (Net, Erp or Sap2) and Elk4 (Sap1) proteins [3,4], which simulated varied proportional of potential protein- protein interactions [4,5].
    [Show full text]
  • New Mechanism Based Approaches for Treating Prostate Cancer Rayna Rosati Wayne State University
    Wayne State University Wayne State University Dissertations 1-1-2017 New Mechanism Based Approaches For Treating Prostate Cancer Rayna Rosati Wayne State University, Follow this and additional works at: https://digitalcommons.wayne.edu/oa_dissertations Part of the Oncology Commons Recommended Citation Rosati, Rayna, "New Mechanism Based Approaches For Treating Prostate Cancer" (2017). Wayne State University Dissertations. 1865. https://digitalcommons.wayne.edu/oa_dissertations/1865 This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState. NEW MECHANISM BASED APPROACHES FOR TREATING PROSTATE CANCER by RAYNA C. ROSATI DISSERTATION Submitted to the Graduate School of Wayne State University, Detroit, Michigan in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY 2017 MAJOR: CANCER BIOLOGY Approved By: Advisor Date DEDICATION This dissertation is dedicated to my family, who made me who I am today with all of their love and support. To my grandmother, Lucy, who just recently lost her battle with lung cancer and who would send me newspaper clippings in the mail about new topics of prostate cancer research. To my siblings, who have always been my best friends. To my father, Daniel, who has been my greatest mentor in life. To my mother, Nanci, who has been there for me through everything and who gave me my creative bone. ii ACKNOWLEDGEMENTS First off, I would like to thank my mentor, Dr. Manohar Ratnam, whose enthusiasm for science is undeniable. Thank you for always being so optimistic and believing I could accomplish this very challenging project.
    [Show full text]
  • Modulation of Transcriptional Activity in Brain Lower Grade Glioma by Alternative Splicing
    A peer-reviewed version of this preprint was published in PeerJ on 14 May 2018. View the peer-reviewed version (peerj.com/articles/4686), which is the preferred citable publication unless you specifically need to cite this preprint. Li J, Wang Y, Meng X, Liang H. 2018. Modulation of transcriptional activity in brain lower grade glioma by alternative splicing. PeerJ 6:e4686 https://doi.org/10.7717/peerj.4686 Modulation of transcriptional activity in brain lower grade glioma by alternative splicing Jin Li 1 , Yang Wang 1 , Xianglian Meng 1 , Hong Liang Corresp. 1 1 College of Automation, Harbin Engineering University, Harbin, Heilongjiang, China Corresponding Author: Hong Liang Email address: [email protected] Proteins that modify the activity of transcription factor (TF), often called modulators, play a vital role in gene transcriptional regulation. Alternative splicing is a critical step of gene processing and it can modulate gene function by adding or removing certain protein domains, and therefore influences the activity of a protein. The objective of this study is to investigate the role of alternative splicing in modulating the transcriptional regulation in brain lower grade glioma (LGG), especially transcription factor ELK1, which is closely related to various diseases, including Alzheimer’s disease and down syndrome. Results showed that changes in the exon inclusion ratio of proteins APP and STK16 are associated with changes in the expression correlation between ELK1 and its targets. Meanwhile, the structural features of the two modulators are strongly associated with the pathological impact of exon inclusion. Our analysis suggests, protein in different splicing level could play different functions on transcription factors, hence induces multiple genes dysregulation.
    [Show full text]
  • Genome-Wide DNA Methylation Analysis of KRAS Mutant Cell Lines Ben Yi Tew1,5, Joel K
    www.nature.com/scientificreports OPEN Genome-wide DNA methylation analysis of KRAS mutant cell lines Ben Yi Tew1,5, Joel K. Durand2,5, Kirsten L. Bryant2, Tikvah K. Hayes2, Sen Peng3, Nhan L. Tran4, Gerald C. Gooden1, David N. Buckley1, Channing J. Der2, Albert S. Baldwin2 ✉ & Bodour Salhia1 ✉ Oncogenic RAS mutations are associated with DNA methylation changes that alter gene expression to drive cancer. Recent studies suggest that DNA methylation changes may be stochastic in nature, while other groups propose distinct signaling pathways responsible for aberrant methylation. Better understanding of DNA methylation events associated with oncogenic KRAS expression could enhance therapeutic approaches. Here we analyzed the basal CpG methylation of 11 KRAS-mutant and dependent pancreatic cancer cell lines and observed strikingly similar methylation patterns. KRAS knockdown resulted in unique methylation changes with limited overlap between each cell line. In KRAS-mutant Pa16C pancreatic cancer cells, while KRAS knockdown resulted in over 8,000 diferentially methylated (DM) CpGs, treatment with the ERK1/2-selective inhibitor SCH772984 showed less than 40 DM CpGs, suggesting that ERK is not a broadly active driver of KRAS-associated DNA methylation. KRAS G12V overexpression in an isogenic lung model reveals >50,600 DM CpGs compared to non-transformed controls. In lung and pancreatic cells, gene ontology analyses of DM promoters show an enrichment for genes involved in diferentiation and development. Taken all together, KRAS-mediated DNA methylation are stochastic and independent of canonical downstream efector signaling. These epigenetically altered genes associated with KRAS expression could represent potential therapeutic targets in KRAS-driven cancer. Activating KRAS mutations can be found in nearly 25 percent of all cancers1.
    [Show full text]
  • MEKK1/JNK Signaling Stabilizes and Activates P53
    Proc. Natl. Acad. Sci. USA Vol. 95, pp. 10541–10546, September 1998 Biochemistry MEKK1/JNK signaling stabilizes and activates p53 SERGE Y. FUCHS*, VICTOR ADLER*, MATTHEW R. PINCUS†, AND ZE’EV RONAI*‡ *Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, NY 10029; and †Department of Pathology and Laboratory Medicine, Brooklyn Veterans Affairs Medical Center and State University of New York Health Science, Brooklyn, NY 11203 Communicated by H. A. Scheraga, Cornell University, Ithaca, NY, July 7, 1998 (received for review May 4, 1998) ABSTRACT Activation of the tumor suppressor p53 by damage is preserved in cells from severe combined immunode- stress and damage stimuli often correlates with induction of ficient mice (10–12), we examined the role of JNK in this stress kinases, Jun-NH2 kinase (JNK). As JNK association response. with p53 plays an important role in p53 stability, in the JNKs are a family of stress kinases induced by change in redox present study we have elucidated the relationship between the potential, heat shock, osmotic shock, UV irradiation, and inflam- JNK-signaling pathway and p53 stability and activity. Expres- matory cytokines (13–16). JNK activity requires mitogen- sion of a constitutively active form of JNKK upstream kinase, activated protein kinases kinase (MEKK) 1–4 which phosphor- mitogen-activated protein kinase kinase kinase (DMEKK1), ylates MKK4/7. MKK4/7, in turn, phosphorylates JNK on resi- increased the level of the exogenously transfected form of p53 dues 183 and 185 (17–20). Activated JNK phosphorylates its in p53 null (10.1) cells as well as of endogenous p53 in MCF7 substrates, c-Jun, ATF2, ELK1, and p53 (3, 13–14, 21).
    [Show full text]
  • An Initiator Element Mediates Autologous Down- Regulation of the Human Type a ␥-Aminobutyric Acid Receptor ␤1 Subunit Gene
    An initiator element mediates autologous down- regulation of the human type A ␥-aminobutyric acid receptor ␤1 subunit gene Shelley J. Russek, Sabita Bandyopadhyay, and David H. Farb* Laboratory of Molecular Neurobiology, Department of Pharmacology, Boston University School of Medicine, 80 East Concord Street, Boston, MA 02118 Edited by Erminio Costa, University of Illinois, Chicago, IL, and approved May 15, 2000 (received for review November 19, 1999) The regulated expression of type A ␥-aminobutyric acid receptor The ␤1 subunit gene is located in the ␤1-␣4-␣2-␥1 gene cluster (GABAAR) subunit genes is postulated to play a role in neuronal on chromosome 4 (12) and is most highly expressed in the adult maturation, synaptogenesis, and predisposition to neurological rat hippocampus. Seizure activity decreases hippocampal ␤1 disease. Increases in GABA levels and changes in GABAAR subunit mRNA levels by about 50% while increasing ␤3 levels (11). gene expression, including decreased ␤1 mRNA levels, have been Because the subtype of ␤ subunit influences the sensitivity of the observed in animal models of epilepsy. Persistent exposure to GABAAR to GABA and to allosteric modulators such as GABA down-regulates GABAAR number in primary cultures of etomidate, loreclezole, barbiturates, and mefenamic acid (13– neocortical neurons, but the regulatory mechanisms remain un- 17), a change in ␤ subunit composition may alter receptor known. Here, we report the identification of a TATA-less minimal function and pharmacology in vivo. Modulation of receptor ␤ promoter of 296 bp for the human GABAAR ␤1 subunit gene that function by phosphorylation is also influenced by subunit is neuron specific and autologously down-regulated by GABA.
    [Show full text]
  • JAG1 Intracellular Domain Acts As a Transcriptional Cofactor That Forms An
    bioRxiv preprint doi: https://doi.org/10.1101/2021.03.31.437839; this version posted March 31, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. JAG1 intracellular domain acts as a transcriptional cofactor that forms an oncogenic transcriptional complex with DDX17/SMAD3/TGIF2 Eun-Jung Kim†1,2, Jung Yun Kim†1,2, Sung-Ok Kim3, Seok Won Ham1,2, Sang-Hun Choi1,2, Nayoung Hong1,2, Min Gi Park1,2, Junseok Jang1,2, Sunyoung Seo1,2, Kanghun Lee1,2, Hyeon Ju Jeong1,2, Sung Jin Kim1,2, Sohee Jeong1,2, Kyungim Min1,2, Sung-Chan Kim3, Xiong Jin1,4, Se Hoon Kim5, Sung-Hak Kim6,7, Hyunggee Kim*1,2 †These authors contributed equally to this work. 1Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul 02841, Republic of Korea 2Institute of Animal Molecular Biotechnology, Korea University, Seoul 02841, Republic of Korea 3Department of Biochemistry, College of Medicine, Hallym University, Chuncheon 24252, Republic of Korea 4School of Pharmacy, Henan University, Kaifeng, Henan 475004, China 5Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul 03722, Republic of Korea 6Department of Animal Science, College of Agriculture and Life Sciences, Chonnam National University, Gwangju 61186, Republic of Korea 7Gwangju Center, Korea Basic Science Institute, Gwangju 61186, Republic of Korea *Correspondence: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.03.31.437839; this version posted March 31, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.
    [Show full text]
  • 1 Loss of ELK1 Has Differential Effects on Age-Dependent Organ Fibrosis
    bioRxiv preprint doi: https://doi.org/10.1101/755694; this version posted September 5, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Loss of ELK1 has differential effects on age-dependent organ fibrosis and integrin expression Running title Aged, ELK1 deficient mice develop fibrosis and altered integrin expression Jennifer T Cairns1, Anthony Habgood1, Rochelle C Edwards-Pritchard1, Chloe Wilkinson1, Iain D Stewart1, Jack Leslie2, Burns C Blaxall3, Katalin Susztak4, Siegfried Alberti5, Alfred Nordheim5, Fiona Oakley2, R Gisli Jenkins1, Amanda L Tatler1. 1 Division of Respiratory Medicine, University of Nottingham, Nottingham University Hospitals, City Campus, Nottingham, NG5 1PB, UK and Respiratory Research Unit, NIHR Biomedical Research Centre, Nottingham University Hospitals Nottingham, UK. 2 Newcastle Fibrosis Research Group, Institute of Cellular Medicine, Faculty of Medical Sciences, 4th Floor, William Leech Building, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK 3 Department of Precision Medicine and Pharmacogenetics, The Christ Hospital Health Network, Cincinnati, Ohio, USA 4 Renal Electrolyte and Hypertension Division, Department of Medicine, Department of Genetics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA 5 Interfaculty Institute of Cell Biology, Tuebingen University, Germany and 6 Leibniz Institute on Aging (FLI), Jena, Germany 1 bioRxiv preprint doi: https://doi.org/10.1101/755694; this version posted September 5, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Comparing Subtypes of Breast Cancer Using a Message-Passing Network
    Dana-Farber Cancer Institute Comparing Subtypes of Breast Cancer Using a Kamrine Poels Message-Passing Network Outline ❖ Breast cancer and its molecular subtypes ❖ Passing Attributes between Networks for Data Assimilation (PANDA) ❖ Luminal A vs. Luminal B breast cancer ❖ Basal-like vs. Luminal B breast cancer Gene Sets ❖ Future goals Molecular Subtypes of Breast Cancer ❖ Four recognized molecular subtypes of breast cancer: ❖ Luminal A ❖ Luminal B ❖ Basal (also called Triple Negative BC) ❖ HER2-positive (ERBB2) ❖ 198 samples came from Bioconductor public website, data is Breast Cancer TRANSBIG ❖ Samples were separated according to molecular subtype using the Subtype Clustering Model[1] 71 samples were Luminal A, 60 samples were Luminal B, 45 samples were Basal-like breast cancer, and 22 samples were HER2+. Luminal A and Luminal B are distinguished by level of proliferation. PANDA Algorithm[2] ❖ Main objective of PANDA is to find agreement between data represented by multiple networks: ❖ Protein-protein interaction ❖ Gene-expression (co-regulation network) ❖ TF-gene interaction (regulatory network) TF-Motif Scan PP interaction0 Network0 Co-regulation0 Responsibility Availability PP interaction1 Network1 Co-regulation1 PANDA estimates the probability that an edge exists in a network and returns that estimate in terms of Z-score units ❖ Responsibility(Rij): information flowing from TF i to gene j TF-Motif Scan (t) (t) Pim Wmj PP interaction0 Network0 Co-regulation0 (t) m Rij = 2 P 2 P (t) + W (t) P (t)W (t) im mj − im mj s m m m Responsibility
    [Show full text]
  • Focused Transcription from the Human CR2/CD21 Core Promoter Is Regulated by Synergistic Activity of TATA and Initiator Elements in Mature B Cells
    Cellular & Molecular Immunology (2016) 13, 119–131 ß 2015 CSI and USTC. All rights reserved 1672-7681/15 $32.00 www.nature.com/cmi RESEARCH ARTICLE Focused transcription from the human CR2/CD21 core promoter is regulated by synergistic activity of TATA and Initiator elements in mature B cells Rhonda L Taylor1,2, Mark N Cruickshank3, Mahdad Karimi2, Han Leng Ng1, Elizabeth Quail2, Kenneth M Kaufman4,5, John B Harley4,5, Lawrence J Abraham1, Betty P Tsao6, Susan A Boackle7 and Daniela Ulgiati1 Complement receptor 2 (CR2/CD21) is predominantly expressed on the surface of mature B cells where it forms part of a coreceptor complex that functions, in part, to modulate B-cell receptor signal strength. CR2/CD21 expression is tightly regulated throughout B-cell development such that CR2/CD21 cannot be detected on pre-B or terminally differentiated plasma cells. CR2/CD21 expression is upregulated at B-cell maturation and can be induced by IL-4 and CD40 signaling pathways. We have previously characterized elements in the proximal promoter and first intron of CR2/CD21 that are involved in regulating basal and tissue-specific expression. We now extend these analyses to the CR2/CD21 core promoter. We show that in mature B cells, CR2/CD21 transcription proceeds from a focused TSS regulated by a non-consensus TATA box, an initiator element and a downstream promoter element. Furthermore, occupancy of the general transcriptional machinery in pre-B versus mature B-cell lines correlate with CR2/CD21 expression level and indicate that promoter accessibility must switch from inactive to active during the transitional B-cell window.
    [Show full text]